Amneal Pharmaceuticals (AMRX) Income from Non-Controlling Interests (2017 - 2026)

Amneal Pharmaceuticals' Income from Non-Controlling Interests history runs 10 years deep, the most recent figure standing at $15.7 million for Q1 2026.

• In Q1 2026, Income from Non-Controlling Interests rose 26.73% year-over-year to $15.7 million; the TTM figure through Mar 2026 stood at $59.2 million (up 30.19% YoY), while the FY2025 annual figure was $55.9 million, up 29.91% from the prior year.
• Income from Non-Controlling Interests for Q1 2026 stood at $15.7 million, up from $14.5 million in the prior quarter.
• The five-year high for Income from Non-Controlling Interests was $17.8 million in Q2 2023, with the low at -$119.3 million in Q2 2022.
• The 5-year median for Income from Non-Controlling Interests is $10.8 million (2024), against an average of $1.5 million.
• The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests tumbled 776.0% in 2022, then jumped 5034.11% in 2023.
• Amneal Pharmaceuticals' Income from Non-Controlling Interests stood at -$1.5 million in 2022, then surged by 447.87% to $5.3 million in 2023, then soared by 94.89% to $10.3 million in 2024, then surged by 40.22% to $14.5 million in 2025, then climbed by 8.6% to $15.7 million in 2026.
• Business Quant data shows AMRX's Income from Non-Controlling Interests at $15.7 million in Q1 2026, $14.5 million in Q4 2025, and $15.8 million in Q3 2025.